IJInsa Joost

Insa Joost

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Insa Joost has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of seasons and heat waves on the incidence of Staphylococcus aureus and Escherichia coli bacteremia - A prospective multicenter study using biometeorological data.

    by Philipp Mathé, Kathrin Graw, Andreas Matzarakis, Máté Elod Maros, David Tobys, Britta Kohlmorgen, Nadja Käding, Silke Peter, Harald Seifert, Petra Gastmeier, et al.

    Climate change and global warming are major threats for human health and impact the burden of infectious diseases. We investigated the effect of heat stress days (max. perceived temperature ≥32°C) on the incidence of Staphylococcus aureus bacteremia (SAB) and Escherichia coli bacteremia (ECB). We performed a post-hoc analysis of a prospective multicenter cohort study with inclusion of all reported SAB and ECB episodes at six tertiary care centers in Germany from 01/2017-12/2019. The effect of the number of heat stress days on the incidence of bacteremia episodes was modelled by a negative binomial regression model with and without underlying seasonal trend. In the prospective multicenter cohort, we included 2870 episodes of SAB and 4421 episodes of ECB. For both entities, we found a significant seasonal variation over the year (ECB peak-to-trough ratio: 1.33, 95% CI: 1.23-1.45, p < 0.001); SAB peak-to-trough ratio: 1.19 (95% CI: 1.07-1.32, p < 0.001), especially in the subgroup of community-acquired ECB (1.47, 95%-CI: 1.32-1.64, p < 0.001). In the model with incorporation of an underlying seasonal trend, we discovered no overall significant association with the number of heat stress days for SAB and ECB. However, in the subgroup of patients with hospital-acquired SAB, we found a significant association after two days of heat (IRR 1.45, 95%-CI: 1.17-1.82, p = 0.001), that remained significant also in a sensitivity analysis focusing on summer days only (IRR 1.50, 95%-CI: 1.18-1.91, p = 0.001). However, after inclusion of an underlying seasonal trend, the incidence of bacteremia cases remained significantly associated with heat stress days only in the subgroup of patients with hospital-acquired SAB. Apart from seasonal trends, heat days did not seem to influence the incidence of SAB and ECB overall. The observed association of SAB with heat days in the subgroup of hospital-acquired SAB needs confirmation in further studies.

  • Open Access

    Antimicrobial Stewardship in oral and maxillofacial surgery: melting the iceberg

    by Insa Joost, Melanie Kempe, Barbara Eirmbter, Colin R. MacKenzie, Lara Schorn

    Objective: Irrational antibiotic consumption contributes to antimicrobial resistance, adverse effects, and rising costs. Antimicrobial Stewardship (AMS) supports rational antibiotic use through restrictive and supportive measures. In oral and maxillofacial surgery (OMFS), antibiotic consumption is consistently high, and evidence-based guidelines are often lacking. We evaluated a multimodal AMS intervention on antibiotic use in an OMFS department. Design: Before–after study. Setting: OMFS department of a German university hospital. Patients: Hospitalized patients treated in the OMFS department. Intervention: For 12 months, the AMS team conducted weekly ward visits, providing recommendations regarding antibiotic therapy and surgical antibiotic prophylaxis (SAP). In parallel, a mandatory consensus guideline covering these aspects was developed and implemented. Antibiotic use, prevalence, duration of therapy, and SAP before, during, and after the intervention were evaluated; clinical outcomes were not assessed. Results: Pre-intervention, over 70% of patients received antibiotics. Median duration of antibiotic therapy and SAP was 12 and 9 days, respectively. Antibiotic consumption reached 63.8 defined daily dosages per 100 patient days, exceeding national values (median 40.1). During the intervention, antibiotic prevalence decreased below 50% and the duration of antibiotic therapy and SAP was shortened to 9 and 3 days, respectively. Antibiotic consumption decreased by 26% whereas national values increased by nearly 50%. After weekly consultations ceased, antibiotic use rose again but remained below national levels. Conclusions: Antibiotic consumption is high in OMFS. Regular AMS support including consensus guidelines can reduce antibiotic use substantially and sustainably. However, clinical outcomes need to be correlated and adequately staffed AMS teams are needed.

  • Open Access

    Nationwide survey on penicillin allergy delabeling among German healthcare professionals: knowledge, attitudes and perceived barriers

    by Insa Joost, Lukas Tometten, Joanne Barry, Alexandra Weber, Till Koch, Hannah Nuernberg, Anne Moeser, Anette Friedrichs, Barbara Eirmbter, Annette Hennigs, et al.

    Purpose: Penicillin allergy (PA) delabeling optimizes antibiotic prescribing and is a recognized antimicrobial stewardship (AMS) tool. We aimed to characterize current practices and knowledge of PA delabeling in German non-allergist healthcare professionals to define barriers and facilitators for a wider implementation of delabeling strategies. Methods: A nationwide web-based, anonymous survey was distributed to physicians and hospital pharmacists. It covered four domains: demographics, access to AMS, allergy assessment and attitude towards PA delabeling. Responses were analysed using descriptive and inferential statistics. Results: A total of 504 responses (249 physicians, 255 pharmacists) were analysed. While 86% of respondents were familiar with the concept of delabeling, only 32% had ever performed it, mostly fewer than 6 times in the past year. 12% of physicians regularly took extended allergy histories, and just 2% always used a standardized method. Only ~ 30% of respondents had onsite access to allergy services. Barriers included lack of time, experience and guidance. Pharmacists frequently cited PA management as outside their role. Despite limited experience, 88% of physicians and 71% of pharmacists expressed interest in delabeling if supported by clear algorithms and institutional support. Conclusion: PA delabeling by non-allergists is of great relevance to physicians and pharmacists in Germany but not routinely integrated in clinical pathways, due to missing guidelines, limited resources and unclear role definitions. However, the results of this study highlight the considerable strong potential for implementing structured delabeling strategies—if they are supported by adequate training, clear protocols and sufficiently resourced antimicrobial stewardship teams.


  • Staphylococcus aureus Bloodstream Infection in Patients with Atopic Dermatitis, or: Think Twice Before Placing a Venous Catheter into Lesional Atopic Skin

    by Philipp J.G. Mathé, Insa Joost, Gabriele Peyerl-Hoffmann, Christian Schneider, Winfried Kern, Siegbert Rieg


  • Staphylococcus aureus bacteremia in patients with rheumatoid arthritis – Data from the prospective INSTINCT cohort

    by Insa Joost, Achim Kaasch, Christine Pausch, Gabriele Peyerl-Hoffmann, Christian Schneider, Reinhard E. Voll, Harald Seifert, Winfried V. Kern, Siegbert Rieg


  • Open Access

    Staphylococcus aureus bacteremia with iliac artery endarteritis in a patient receiving ustekinumab

    by Insa Joost, Johannes Steinfurt, Philipp T. Meyer, Winfried V. Kern, Siegbert Rieg

    Ustekinumab (Stelara®), a human monoclonal antibody targeting the p40-subunit of interleukin (IL)-12 and IL-23, is indicated for moderate to severe plaque psoriasis and psoriatic arthritis. In large multicenter, prospective trials assessing efficacy and safety of ustekinumab increased rates of severe infections have not been observed so far. Here, we report the case of a 64-year old woman presenting with chills, pain and swelling of her right foot with dark maculae at the sole, and elevated inflammatory markers. She had received a third dose of ustekinumab due to psoriatic arthritis three days before admission. Blood cultures revealed growth of Staphylococcus aureus and imaging showed a thickening of the aortic wall ventral the bifurcation above the right internal iliac artery, resembling an acute bacterial endarteritis. Without the evidence of aneurysms and in absence of foreign bodies, the decision for conservative management was made. The patient received four weeks of antibiotic therapy with intravenous flucloxacillin, followed by an oral regime with levofloxacin and rifampicin for an additional four weeks. Inflammatory markers resolved promptly and the patient was discharged in good health. To our knowledge, this is the first report of a severe S. aureus infection in a patient receiving ustekinumab. Albeit ustekinumab is generally regarded as a safe drug, severe bacterial infections should always be included in the differential diagnosis of elevated inflammatory markers in patients receiving biologicals as these might present with nonspecific symptoms and fever might be absent. Any effort to detect deep-seated or metastatic infections should be made to prevent complications and to secure appropriate treatment. Although other risk factors for an invasive staphylococcal infection like psoriasis, recent corticosteroid injection, or prior hospitalisations were present, and therefore a directive causative link between the S. aureus bacteraemia and ustekinumab can not be drawn, we considered the reporting of this case worthwhile to alert clinicians as we believe that ongoing pharmacovigilance to detect increased risks for rare but severe infections beyond phase II and phase III trials in patients treated with biologicals is essential.